Also Sight Sciences just announced that their clinical trial has been accepted for peer review, and should be ready by 31 December. This is significant as it fully complies with the new evidence criteria set in the LCD, and so even if the industry is unable to appeal the LCD on the basis of procedural and legal flaws, as well as existing evidence, this new evidence will be sufficient to gain coverage under the new criteria. Importantly, the LCD is targeting the overall procedure, not specific devices, so this evidence will support canaloplasty generally regaining coverage, and hence iTrack Advance will benefit from the release of this study. Then it'll be up to doctors to decide which device they prefer, not insurers...
Nova Eye Medical has two similar trials on the way as well, MAGIC and CATALYST, which will further support greater market access for iTrack Advance. MAGIC directly compares iTrack Advance to Omni, and I suspect iTrack Advance will significantly outperform
Also Sight Sciences just announced that their clinical trial has...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.010(4.44%) |
Mkt cap ! $53.77M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.5¢ | 22.0¢ | $170K | 755.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 42905 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
0.010 ( 2.27 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.0¢ | 22.0¢ | 419541 | ||
| Last updated 15.49pm 17/06/2024 ? | |||||
| EYE (ASX) Chart |
